Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC Nab-paclitaxel with Gemcitabine and Cisplatin in Biliary Tract Cancer with Peritoneal Metastases
NCT05285358Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2022
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in biliary tract cancer (BTC), sponsored by City of Hope. Primary endpoint: Incidence of adverse events. Started Sep 2022; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05285358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285358.